Dec'04 | Dec'05 | Dec'06 | Dec'07 | Dec'08 | Dec'09 | Dec'10 | Dec'11 | Dec'12 | Dec'13 | Dec'14 | Dec'15 | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Return on Capital Employed (ROCE) | (46.9%) | (50.3%) | (37.6%) | (74.3%) | (74.1%) | (61.6%) | (56.3%) | 7.2% | (2.0%) | (29.0%) | (36.0%) | (25.2%) | (0.3%) | 8.2% | 51.3% | 15.5% | 28.3% | 22.0% | 24.9% | 20.3% |
Discover the top 20 best undervalued stocks to buy for Jan 2025, listed on the Nasdaq or NYSE.
Discover the top 20 best undervalued large-cap growth stocks to buy for Jan 2025, listed on the Nasdaq or NYSE.
Discover the top 20 best undervalued high-yield dividend stock that offers both growth potential and attractive dividend returns for Jan 2025.
As of today, Microsoft Corp's last 12-month Return on Capital Employed (ROCE) is (6.0%), based on the financial report for Sep 30, 2024 (Q3 2024). The average annual Return on Capital Employed (ROCE) for Vertex Pharmaceuticals Incorporated have been 17.0% over the past three years, and 20.0% over the past five years.
As of today, Vertex Pharmaceuticals Incorporated's Return on Capital Employed (ROCE) is (6.0%), which is higher than industry median of (50.6%). It indicates that Vertex Pharmaceuticals Incorporated's Return on Capital Employed (ROCE) is Good.